National centralized procurement policy achieved dramatic cost reductions (e.g., tofacitinib DDDc decreased by 93.3%), directly driving increased utilization of tsDMARDs and bDMARDs. This study provides empirical evidence that aggressive pharmaceutical pricing policies can rapidly improve access to advanced rheumatologic therapies in resource-limited settings, offering a replicable model for healthcare systems worldwide. Key Points • Overall disease-modifying antirheumatic drugs (DMARDs) use showed modest growth from 2018 to 2022. • tsDMARDs and bDMARDs exhibited rapid increases in use and revenue. • Methotrexate and leflunomide remained key csDMARDs in clinical practice.

8 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha)

tofacitinib • Cosentyx (secukinumab) • Simponi (golimumab) • leflunomide

15d

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov)

P4, N=10, Not yet recruiting, University of California, San Francisco | Initiation date: Jan 2026 --> Aug 2026

15 days ago

Trial initiation date

5-fluorouracil • Jakafi (ruxolitinib) • hydroxychloroquine • cyclosporine • roflumilast • tofacitinib • Cosentyx (secukinumab) • Dupixent (dupilumab) • Ilumya (tildrakizumab-asmn) • chloroquine phosphate

15d

ODEN: Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (clinicaltrials.gov)

P=N/A, N=102, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Sep 2025

15 days ago

Trial completion • Trial completion date • Trial primary completion date

tofacitinib

16d

TB risk during treatment with biological agents and Janus kinase inhibitors: an umbrella review. (PubMed, Int J Tuberc Lung Dis)

Risk of bias was assessed using ROBIS.RESULTSAnti-TNF monoclonal antibodies (infliximab, adalimumab) were consistently associated with the highest TB risk (odds ratio commonly 3-5), with greater proportions of disseminated/extra-pulmonary disease compared to etanercept...JAK inhibitors (notably tofacitinib) conferred geographically variable risk, higher in intermediate/high-burden countries. Immune checkpoint inhibitors, especially PD-1/PD-L1 agents, were linked to TB incidence far above background rates.CONCLUSIONTB risk varies markedly across biologic and targeted agents. Risk-based TB infection screening and tailored prophylaxis beyond anti-TNF therapy are warranted, particularly in endemic regions..

16 days ago

Journal

IL6 (Interleukin 6) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)

tofacitinib

17d

SMART-JIA: Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (clinicaltrials.gov)

P3, N=400, Recruiting, Duke University | Trial primary completion date: Jun 2026 --> Dec 2026

17 days ago

Trial primary completion date

tofacitinib • Orencia (abatacept)

18d

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL (2024-516570-30-00)

P1/2, N=12, Not yet recruiting, Centre Hospitalier De Versailles

18 days ago

New P1/2 trial

Venclexta (venetoclax) • everolimus • azacitidine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • tofacitinib

27d

TARA: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (clinicaltrials.gov)

P3, N=459, Active, not recruiting, Hangzhou Highlightll Pharmaceutical Co., Ltd | Trial completion date: Dec 2028 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Jan 2026

27 days ago

Trial completion date • Trial primary completion date • Head-to-Head

tofacitinib

29d

TARA: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (clinicaltrials.gov)

P3, N=459, Active, not recruiting, Hangzhou Highlightll Pharmaceutical Co., Ltd | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2028 | Trial primary completion date: Feb 2025 --> Jul 2026

29 days ago

Enrollment closed • Trial completion date • Trial primary completion date • Head-to-Head

tofacitinib

30d

MISSION-1: Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1 (clinicaltrials.gov)

P2, N=92, Recruiting, University of Colorado, Denver

30 days ago

New P2 trial

tofacitinib

Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center. (PubMed, Ther Adv Musculoskelet Dis)

Case 1 (PsA): Long-standing disease (24 years) failed optimized adalimumab; following DTT, disease activity in psoriatic arthritis (DAPSA) score improved from high disease activity (36) to low disease activity (8). Our real-world findings demonstrate improved disease control and safety when monotherapy fails. Future prospective studies are essential to optimize the selection, dosing, and long-term safety of DTT.

1 month ago

Journal

CRP (C-reactive protein)

tofacitinib

EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov)

P=N/A, N=4000, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

tofacitinib • Entyvio (vedolizumab) • Simponi (golimumab)

Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis (clinicaltrials.gov)

P=N/A, N=130, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Apr 2030 --> Dec 2029 | Trial primary completion date: Apr 2030 --> Dec 2029

1 month ago

Trial completion date • Trial primary completion date

methotrexate • tofacitinib